Lyell Immunopharma, Inc.

Direct answer

Lyell Immunopharma, Inc. is publicly traded on NASDAQ under the ticker LYEL.

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company’s lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical...

Can you invest in Lyell Immunopharma, Inc.?

Yes. Lyell Immunopharma, Inc. is publicly traded on NASDAQ under the ticker LYEL.

View deeper analysis

View detailed research on MarketSnap, including financials, valuation tools, and analyst context.

Open research for Lyell Immunopharma, Inc.

Detailed equity research is provided by MarketSnap.